Ally Bridge Group’s aTyr Pharma ATYR Stock Holding History

Ally Bridge Group’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-600,000	Closed	-$433K	–	32
2025 Q3	$433K	Buy	+600,000	New	+$2.72M	0.26%	24

Other funds holding ATYR

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ally Bridge Group's ATYR Position: Q3 2025 in Review

Ally Bridge Group sold out of aTyr Pharma (ATYR) in Q3 2025, closing a stake of 287,720 shares — an estimated $1.3M sold.

Ally Bridge Group first reported a position in ATYR in Q4 2024 and held it in 3 quarters. The position peaked at $2.53M in Q4 2024. 103 funds tracked by Wall St. Rank hold ATYR as of Q3 2025.

Ally Bridge Group reported no remaining aTyr Pharma position as of Q3 2025 after selling out during the quarter.
Ally Bridge Group sold 287,720 aTyr Pharma shares in Q3 2025, an estimated $1.3M.
Ally Bridge Group first reported a position in aTyr Pharma in Q4 2024 and held it in 3 quarters.
Ally Bridge Group's aTyr Pharma position peaked at $2.53M in Q4 2024.
103 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2025.

Based on Ally Bridge Group's 13F filing for Q3 2025, filed 14 Nov 2025.